FCMV

Foresite Capital Management VI Portfolio holdings

AUM $259M
1-Year Est. Return 22.15%
This Quarter Est. Return
1 Year Est. Return
+22.15%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$259M
AUM Growth
+$81M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
21
New
Increased
Reduced
Closed

Top Buys

1
+$14.5M
2
+$11.8M
3
+$1.47M
4
CASI icon
CASI Pharmaceuticals
CASI
+$320K

Top Sells

1
+$8.82M
2
+$7.67M
3
+$5.01M
4
CGEM icon
Cullinan Oncology
CGEM
+$4.47M
5
GPCR icon
Structure Therapeutics
GPCR
+$4.36M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$4.37B
$89.5M 34.57%
2,221,474
RAPT icon
2
RAPT Therapeutics
RAPT
$1.67B
$40.3M 15.57%
1,562,500
CNTA
3
Centessa Pharmaceuticals
CNTA
$3.84B
$31.9M 12.31%
1,314,019
+60,640
VSTM icon
4
Verastem
VSTM
$474M
$23.1M 8.92%
2,615,120
+1,338,600
ALMS
5
Alumis Inc
ALMS
$3.16B
$16.9M 6.55%
4,247,670
DNLI icon
6
Denali Therapeutics
DNLI
$3.29B
$14.5M 5.61%
+1,000,000
CRVS icon
7
Corvus Pharmaceuticals
CRVS
$1.76B
$12.8M 4.93%
1,731,233
AKRO
8
DELISTED
Akero Therapeutics
AKRO
$11.6M 4.49%
244,900
KYMR icon
9
Kymera Therapeutics
KYMR
$5.69B
$8.28M 3.2%
146,332
HNGE
10
Hinge Health
HNGE
$3.29B
$6.63M 2.56%
135,000
RNA icon
11
Avidity Biosciences
RNA
$10.9B
$1.74M 0.67%
40,000
CASI icon
12
CASI Pharmaceuticals
CASI
$19.7M
$1.63M 0.63%
979,956
+192,835
ALLO icon
13
Allogene Therapeutics
ALLO
$344M
– –
-2,875,357
CGEM icon
14
Cullinan Oncology
CGEM
$711M
– –
-594,025
EWTX icon
15
Edgewise Therapeutics
EWTX
$3B
– –
-585,000
GPCR icon
16
Structure Therapeutics
GPCR
$6.35B
– –
-210,000
IDYA icon
17
IDEAYA Biosciences
IDYA
$3.05B
– –
-144,468
SYRE icon
18
Spyre Therapeutics
SYRE
$2.54B
– –
-70,000
VRDN icon
19
Viridian Therapeutics
VRDN
$3.18B
– –
-1,974
XENE icon
20
Xenon Pharmaceuticals
XENE
$3.3B
– –
-160,000
BCAX
21
Bicara Therapeutics
BCAX
$913M
– –
-949,260